(VIII): The Eight Study and Immunologic Response Sub-study
Monitoring of Physiologic Changes Associated With Immune System Activation Associated With Vaccination Against the SARS-CoV-2 Virus: Vaccine-Induced Inflammation Identification
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maged Gendy
- Phone Number: 708-802-3797
- Email: maged.gendy@physiq.com
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 3A3
- Recruiting
- Cell Carta
-
Contact:
- Maged Gendy
- Phone Number: 708-802-3797
- Email: maged.gendy@physiq.com
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60606
- Recruiting
- physIQ
-
Contact:
- Maged Gendy
- Phone Number: 708-802-3797
- Email: maged.gendy@physiq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Is 18 years of age or older.
- Is able to speak and read English.
- Plan to receive either the Moderna or Pfizer vaccine (mRNA vaccine).
- No known prior COVID-19 infection.
Exclusion Criteria:
- Known allergy to the adhesive used on the VitalPatch.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Physiology Monitoring
The study's objective is to test the hypothesis that immune system activation and subsequent systemic inflammation can be detected through continuously tracking multiple bio signals including physiologic variables (ECG, skin temperature and their derivatives) and behavioral variables (activity and sleep from accelerometers) collected during routine activities of daily living using wearable biosensors.
|
|
Physiology & Immune Monitoring
A limited sub-study including 30 individuals enrolled in the primary study (not retrospective group) will incorporate serial blood draws relative to the vaccine doses.
The purpose of the serologies and immunoassays is to explore the correlation an individual's development of a vaccine-induced immune response with changes in the continuous physiologic data surrounding the immunization process.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Collect bio signal data before and after vaccination in ~100 individuals using one or more wearable biosensors.
Time Frame: December, 2022
|
December, 2022
|
|
Evaluate the relationship between the MCI and individual bio signals parameters and the subjective symptoms experienced by participants.
Time Frame: December, 2022
|
December, 2022
|
|
Explore the association between these objectively measured physiologic changes and vaccine-induced humoral and T-cell responses.
Time Frame: December, 2022
|
December, 2022
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steve Steinhubl, MD, CMO
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CTP-024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.